Geode Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-417,858
| Closed | -$2.44M | – | 4883 |
|
|
2022
Q4 | $2.44M | Buy |
417,858
+9,369
| +2% | +$49.3K | ﹤0.01% | 2965 |
|
|
2022
Q3 | $2.74M | Buy |
408,489
+164,116
| +67% | +$995K | ﹤0.01% | 2973 |
|
|
2022
Q2 | $1.03M | Sell |
244,373
-8,811
| -3% | -$34.9K | ﹤0.01% | 3410 |
|
|
2022
Q1 | $853K | Sell |
253,184
-3,959
| -2% | -$12.6K | ﹤0.01% | 3687 |
|
|
2021
Q4 | $810K | Sell |
257,143
-86,557
| -25% | -$288K | ﹤0.01% | 3808 |
|
|
2021
Q3 | $1.12M | Buy |
343,700
+23,078
| +7% | +$80.9K | ﹤0.01% | 3619 |
|
|
2021
Q2 | $1.35M | Sell |
320,622
-217,899
| -40% | -$922K | ﹤0.01% | 3451 |
|
|
2021
Q1 | $2.69M | Buy |
538,521
+157,154
| +41% | +$1.27M | ﹤0.01% | 3114 |
|
|
2020
Q4 | $4.82M | Buy |
381,367
+16,050
| +4% | +$183K | ﹤0.01% | 2626 |
|
|
2020
Q3 | $3.59M | Buy |
365,317
+8,404
| +2% | +$82.8K | ﹤0.01% | 2577 |
|
|
2020
Q2 | $3.55M | Buy |
356,913
+19,633
| +6% | +$188K | ﹤0.01% | 2518 |
|
|
2020
Q1 | $2.98M | Buy |
337,280
+73,780
| +28% | +$728K | ﹤0.01% | 2445 |
|
|
2019
Q4 | $2.43M | Buy |
263,500
+17,736
| +7% | +$126K | ﹤0.01% | 2893 |
|
|
2019
Q3 | $1.45M | Buy |
245,764
+397
| +0.2% | +$4.21K | ﹤0.01% | 3094 |
|
|
2019
Q2 | $2.94M | Buy |
245,367
+18,279
| +8% | +$197K | ﹤0.01% | 2708 |
|
|
2019
Q1 | $2.74M | Buy |
227,088
+19,691
| +9% | +$290K | ﹤0.01% | 2665 |
|
|
2018
Q4 | $2.6M | Sell |
207,397
-19,367
| -9% | -$267K | ﹤0.01% | 2615 |
|
|
2018
Q3 | $3.37M | Buy |
226,764
+24,016
| +12% | +$378K | ﹤0.01% | 2610 |
|
|
2018
Q2 | $3.41M | Buy |
202,748
+18,953
| +10% | +$368K | ﹤0.01% | 2547 |
|
|
2018
Q1 | $4.21M | Buy |
183,795
+16,211
| +10% | +$361K | ﹤0.01% | 2349 |
|
|
2017
Q4 | $4.33M | Buy |
167,584
+36,982
| +28% | +$745K | ﹤0.01% | 2288 |
|
|
2017
Q3 | $1.93M | Buy |
130,602
+2,420
| +2% | +$35.1K | ﹤0.01% | 2774 |
|
|
2017
Q2 | $1.79M | Sell |
128,182
-14,558
| -10% | -$215K | ﹤0.01% | 2796 |
|
|
2017
Q1 | $2.44M | Buy |
142,740
+838
| +0.6% | +$10.1K | ﹤0.01% | 2548 |
|
|
2016
Q4 | $1.46M | Sell |
141,902
-6,326
| -4% | -$57.8K | ﹤0.01% | 2807 |
|
|
2016
Q3 | $1.5M | Buy |
148,228
+7,759
| +6% | +$84.8K | ﹤0.01% | 2723 |
|
|
2016
Q2 | $1.58M | Buy |
140,469
+48
| +0% | +$611 | ﹤0.01% | 2643 |
|
|
2016
Q1 | $1.92K | Buy |
140,421
+10,642
| +8% | +$153K | ﹤0.01% | 2496 |
|
|
2015
Q4 | $2.46M | Buy |
129,779
+2,393
| +2% | +$52K | ﹤0.01% | 2333 |
|
|
2015
Q3 | $2.39M | Buy |
127,386
+32,991
| +35% | +$561K | ﹤0.01% | 2328 |
|
|
2015
Q2 | $1.41M | Buy |
94,395
+11,247
| +14% | +$171K | ﹤0.01% | 2717 |
|
|
2015
Q1 | $1.26M | Buy |
83,148
+52,287
| +169% | +$730K | ﹤0.01% | 2742 |
|
|
2014
Q4 | $411K | Buy |
30,861
+4,694
| +18% | +$60.6K | ﹤0.01% | 3273 |
|
|
2014
Q3 | $329K | Buy |
26,167
+5,225
| +25% | +$50.7K | ﹤0.01% | 3354 |
|
|
2014
Q2 | $211K | Sell |
20,942
-3,288
| -14% | -$31.8K | ﹤0.01% | 3504 |
|
|
2014
Q1 | $325K | Buy |
+24,230
| New | +$342K | ﹤0.01% | 3326 |
|
Geode Capital Management's CNCE Position: Q1 2023 in Review
Geode Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 417,858 shares — an estimated $2.44M sold.
Geode Capital Management first reported a position in CNCE in Q1 2014 and held it in 36 quarters. The position peaked at $4.82M in Q4 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Geode Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Geode Capital Management sold 417,858 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.44M.
- Geode Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 36 quarters.
- Geode Capital Management's Concert Pharmaceuticals, Inc. position peaked at $4.82M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Geode Capital Management's 13F filing for Q1 2023, filed 15 May 2023.